Read my take on promising new data from HIVR4P 2021 on monthly oral islatravir and injectable cabotegravir as long-acting PrEP options.
Read my take on promising new data from HIVR4P // Virtual 2021 on broadly neutralizing HIV antibody immunoprophylaxis and multipurpose prevention technologies under investigation for HIV prevention.
In this downloadable slideset, CCO’s expert faculty members summarize key studies from this important conference, including clinical data on new PrEP options, implementation strategies, multipurpose prevention technologies, and an emerging treatment.
In this Webcast, Dr. Kenneth Mayer summarizes key studies from this important conference, including clinical data on new/emerging PrEP options, implementation strategies, and multipurpose prevention technologies.
In this Webinar, Dr. Linda-Gail Bekker summarizes key studies from this important conference, including clinical data on new/emerging PrEP options, implementation strategies, and multipurpose prevention technologies.
Hear insights from Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, on some of the most important new data reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, implantable options, multipurpose prevention strategies, and key aspects of PrEP implementation
Conference organizers are using social media to communicate with delegates attending the meeting.
Social Media
Join the #HIVR4P conversation
Facebook, Twitter, Instagram, YouTube.
For more information about these resources and HIVr4P 2021, go to www.hivr4p.org.
NAM is the official provider of online scientific news reporter for the conference.
To view the coverage and to sign up for the bulletins, go to www.aidsmap.com/conference/hivr4P-2021.
Showing 78 news articles about Sexually transmitted infections prevention
African studies explore reasons to start, stick with or stop PrEP
HIV self-testing increases uptake of HIV testing, but with poorer linkage to care
Nearly a million have started taking PrEP worldwide – only a third of UNAIDS’ 2020 target
A triumph for injectable PrEP, but a sobering result for oral PrEP
Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’
Anthony Fauci: “I don’t do this because I’m a hero. I do it because it’s necessary.”
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.